한국맥널티
Financials
Valuation Metrics
한국맥널티's Market Cap is ₩224B. At end of 2025 it was ₩357B. Ranked #2235 of 2,436 in KR market (top 92%), #1464 of 1,649 on KOSDAQ (top 89%), #79 of 84 in Food, Beverage & Tobacco (top 94%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 22.45B KRW | KR#2,235/2,436 Sec#79/84 |
| Revenue | 95.26B KRW | KR#1,418/2,436 Sec#66/84 |
| Net Income | -592.4M KRW | KR—/2,436 Sec—/84 |
| Total Assets | 84.95B KRW | KR#1,864/2,436 Sec#72/84 |
| Net Assets | 37.59B KRW | KR#2,063/2,436 Sec#76/84 |
| Employees | 114 | KR#1,531/2,436 Sec#61/84 |
| Value | ||
| P/B | 0.60x | KR#1,024/2,436 Sec#58/84 |
| P/S | 0.24x | KR#467/2,436 Sec#40/84 |
| FCF Yield | 22.28% | KR#296/2,436 Sec#29/84 |
| Profitability | ||
| ROE | -1.58% | KR#1,593/2,436 Sec#59/84 |
| ROA | -0.70% | KR#1,568/2,436 Sec#58/84 |
| Op. Margin | -1.57% | KR#1,717/2,436 Sec#75/84 |
| Revenue Growth | -4.26% | KR#1,668/2,436 Sec#69/84 |
| Financial Health | ||
| Debt Ratio | 225.98% | KR#1,876/2,436 Sec#52/84 |
| Total Debt | 35.23B KRW | KR#1,124/2,436 Sec#60/84 |
| FCF | 5.00B KRW | KR#906/2,436 Sec#49/84 |
| Cash | 2.04B KRW | KR#2,241/2,436 Sec#78/84 |
| Current Ratio | 1.15x | KR#1,655/2,436 Sec#41/84 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,436 Sec—/84 |
| Performance | ||
| 1Y Return | -47.01% | KR#1,947/2,436 Sec#73/84 |
| 1M Return | -2.63% | KR#805/2,436 Sec#49/84 |
| From 52W High | -52.89% | KR#1,227/2,436 Sec#64/84 |
| 1Y MDD | -59.83% | KR#1,406/2,436 Sec#71/84 |
| Trading | ||
| Volume | 6,938 shares | KR#2,022/2,436 Sec#57/84 |
| Foreign Own. | 2.08% | KR—/2,436 Sec—/84 |
| Per Share | ||
| EPS | -37 KRW | KR—/2,436 Sec—/84 |
| BPS | 3,139 KRW | KR#1,786/2,436 Sec#70/84 |
Company Info
Korea McNulty, established in 1997 and headquartered in Cheonan, Chungcheongnam-do, primarily engages in coffee manufacturing and processing. In 2020, it spun off its pharmaceutical business, establishing McNulty Pharm Co., Ltd. and McNulty Bio Co., Ltd. as affiliates. The company's coffee division covers the entire process from green beans to roasted coffee products, while its pharmaceutical division produces general and specialized pharmaceuticals, alongside CMO and CSO services. Korea McNulty is expanding its business by entering large distribution channels, increasing B2B sales, launching a coffee academy, and pursuing the conversion of its Chinese sales subsidiary.